Sector News

Abbott elects CEO Ford chairman of the board as predecessor White retires after 40 years

December 19, 2021
Life sciences

As his second year at the helm of the medtech giant draws to a close, Abbott CEO Robert Ford is adding a new title to his résumé.

The company’s board of directors voted to make Ford chairman of the board. The appointment took effect Dec. 10, at which time Miles White stepped down from the role he’d held for more than 20 years—comprising more than half of the former chief executive’s nearly four decades at Abbott.

“We’re grateful for Miles’ leadership and his exceptional work to transform Abbott into the leading health technology company that it is today,” said William Osborn, lead director and chair of the board’s nominations and governance committee. “Robert has continued to strengthen Abbott’s position by advancing our industry-leading pipeline while managing the company’s significant contributions during the pandemic.”

White’s retirement follows his decision to step down as CEO in March 2020. He’d held the top job at Abbott since 1998 and was tapped to lead the board of directors the following year.

“It’s been my privilege to serve Abbott and its many stakeholders, reshaping the company to keep it relevant and strong while medicine, technology and society have evolved,” White said. “Abbott will be in good hands with Robert’s leadership, and I want to thank the board and my colleagues—current and past—for their support during my tenure.”

Ford succeeded White as CEO last year following a decadeslong tenure of his own with the company. After joining in 1996, Ford spent the next 25 years working his way through the ranks of Abbott’s diabetes care, nutrition and medical device businesses.

That culminated in his being named president and chief operating officer in 2018. His unanimous appointment as CEO—and election to the board of directors—followed just about a year later, then took effect in early 2020. In his first year, Ford’s compensation nearly doubled, surging to more than $20.4 million in 2020.

“I want to thank Miles for all he’s done for Abbott and the people we serve, as well as his mentorship and friendship throughout my career,” Ford said in a statement about his latest appointment. “It’s my honor to work alongside the board and my global team to deliver on the unprecedented opportunities in front of us, so Abbott continues to lead in the reshaping of the future of healthcare.”

Though Ford’s stint as CEO so far has closely mirrored the onset and spread of the COVID-19 pandemic, he’s already led the company to a near-total recovery. By the second quarter of this year, even as COVID test sales slipped, Abbott registered a jump of about 11% in total global sales compared to the same period in 2019 and excluding COVID-related earnings.

In the following months, the company saw yet another bump in revenues as COVID testing rebounded, sending its virus-related diagnostic sales to nearly $2 billion for the third quarter of the year.

by Andrea Park

Source: fiercebiotech.com

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend